IN THE CLAIMS

Please AMEND the claims as follows. This listing of the claims will replace all prior versions and listings of the claims in the application.

1-18. (Cancelled)

19. (Currently Amended) A fusion polypeptide, comprising

a. a peptide of 3 to 30 amino acids ~~capable of~~ comprising the amino acid sequence RGD or NGR, wherein said peptide selectively ~~binding~~ binds said fusion polypeptide to a tumor vessel endothelial cell[[s]]; and

b. a tissue factor or a fragment thereof ~~capable of~~ that ~~activating~~ activates blood clotting when said fusion polypeptide selectively binds to said tumor vessel endothelial cell[[s]], wherein said tissue factor or said fragment thereof comprises an amino acid sequence selected from the group consisting of a sequence having at least 95% homology to SEQ ID NO: 1, a sequence having at least 95% homology to SEQ ID NO: 2, a sequence having at least 95% homology to amino acid positions 11 - 218 of SEQ ID NO: 2, a sequence having at least 95% homology to amino acid positions 1 - 210 of SEQ ID NO: 2, and a sequence having at least 95% homology to amino acid positions 1 - 214 of SEQ ID NO: 2, and said peptide of 3 to 30 amino acids is coupled ~~directly or via a linker having up to 15 amino acids~~ to the C-terminus of said tissue factor or said fragment thereof.

20. (Currently Amended) The fusion polypeptide according to claim 19, ~~wherein said coupling is via~~ further comprising a linker having up to 15 amino acids linked to the C-terminus of said tissue factor or said fragment thereof.

21. (Currently Amended) The fusion polypeptide according to claim 19, wherein ~~said coupling~~ said peptide is coupled directly to said tissue factor or said fragment thereof ~~is direct~~.

22 - 23. (Canceled)

24. (Currently Amended) The fusion polypeptide according to claim 19, wherein said peptide of 3 to 30 amino acids has a linear structure or a cyclic structure.

25. (Canceled)

26. (Currently Amended) The fusion polypeptide according to claim ~~25~~ 19, wherein said peptide of 3 to 30 amino acids is selected from the group consisting of GRGDSP (SEQ ID NO: 33) and GNGRAHA (SEQ ID NO: 34).

27. (Currently Amended) The fusion polypeptide according to claim ~~25~~ 19, wherein said peptide of 3 to 30 amino acids is selected from the group consisting of GCNGRCG (SEQ ID NO:36), GCNGRCVSGCAGRC (SEQ ID NO:37), GCVLNGRMEC (SEQ ID NO:38), and GALNGRSHAG (SEQ ID NO:35).

28. (Currently Amended) The fusion polypeptide according to claim ~~25~~ 19, wherein said fusion polypeptide has the sequence selected from the group consisting of SEQ ID NOs: 3-8.

29. (Currently Amended) A nucleic acid molecule encoding a fusion polypeptide according to claim 19.

30. (Currently Amended) The nucleic acid molecule according to claim 29, wherein said fusion polypeptide has the sequence selected from the group consisting of SEQ ID NOs: 10-15.

31. (Currently Amended) A vector comprising a nucleic acid molecule according to claim 29.

32. (Currently Amended) A cell comprising a nucleic acid molecule according to claim 29.

33. (Previously Presented) A cell comprising a vector according to claim 31.

34. (Currently Amended) A pharmaceutical composition comprising a fusion polypeptide according to claim 19 and a pharmaceutical carrier, excipient, adjuvant, or combination thereof.

35. (Currently Amended) A pharmaceutical composition comprising a nucleic acid molecule according to claim 29 and a pharmaceutical carrier, excipient, adjuvant, or combination thereof.

36. (Currently Amended) A pharmaceutical composition comprising a vector according to claim 31 and a pharmaceutical carrier, excipient, adjuvant, or combination thereof.

37. (Currently Amended) A pharmaceutical composition comprising a cell according to claim 32, and a pharmaceutical carrier, excipient, adjuvant, or combination thereof.

38. (Canceled)

39. (Currently Amended) A method of treating a patient with a neoplastic disease using a pharmaceutical composition according to claim 34, comprising administering said pharmaceutical composition to said patient, wherein said neoplastic disease is selected from the group consisting of lung carcinomas, sarcomas, breast cancer, malignant melanomas, prostate cancers and other urogenital tumors, endocrine-active tumors, and fibrosarcoma.

40. (Canceled)

41. (New) The method according to claim 39, wherein said administering is selected from the group consisting of intravenously, subcutaneously, orally, and intraperitoneal administration.